Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2102247 | 0.91 | TAAR1 (0.41) | TAAR1HTR1AKCNH2SCN5AGABRA1 | |
| SCHEMBL2100719 | 0.89 | TAAR1 (0.40) | TAAR1HTR1AKCNH2SCN5AGABRA1 | |
| SCHEMBL2103378 | 0.89 | TAAR1 (0.40) | TAAR1HTR1AKCNH2SCN5A | |
| Detomidine SCHEMBL4628630 | 0.89 | TAAR1 (0.40) | TAAR1HTR1AKCNH2SCN5A | |
| SCHEMBL10740522 | 0.85 | TAAR1 (0.41) | TAAR1HTR1AKCNH2SCN5AGABRA1 | |
| SCHEMBL2102800 | 0.84 | TAAR1 (0.37) | TAAR1HTR1APDK2 | |
| SCHEMBL11047730 | 0.84 | TAAR1 (0.36) | TAAR1HTR1AKCNH2SCN5AGABRA1 | |
| SCHEMBL3176254 | 0.82 | KDM5B (0.36) | TAAR1HTR1AKDM5B | |
| SCHEMBL2103783 | 0.79 | TAAR1 (0.46) | TAAR1HTR1A | |
| SCHEMBL4626492 | 0.78 | LMNA (0.39) | SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101374832-B | Use of 4-imidazole derivatives for CNS disorders | HOFFMANN LA ROCHE | 2013-03-06 | — | — | CN | claimed |
| EP-1981880-B1 | USE OF 4-IMIDAZOLE DERIVATIVES FOR CNS DISORDERS | HOFFMANN LA ROCHE (CH) | 2010-02-24 | — | — | EP | claimed |
| CN-101374832-A | Use of 4-imidazole derivatives for CNS disorders | HOFFMANN LA ROCHE (CH) | 2009-02-25 | — | — | CN | claimed |
| EP-1981880-A2 | USE OF 4-IMIDAZOLE DERIVATIVES FOR CNS DISORDERS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-22 | — | — | EP | claimed |
| US-20070197622-A1 | Methods for treating CNS disorders with 4-imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | claimed |
| WO-2007085556-A2 | USE OF 4-IMIDAZOLE DERIVATIVES FOR CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | claimed |
| US-4443466-A | DIURETICS, SEDATIVES, ANALGESICS | Farmos-Yhtyma OY (Farmos Group Ltd.) (FI) | 1984-04-17 | — | — | US | claimed |
| CN-101374832-B | Use of 4-imidazole derivatives for CNS disorders | HOFFMANN LA ROCHE | 2013-03-06 | — | — | CN | disclosed |
| US-8158668-B2 | Methods for treating CNS disorders with 4-imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-04-17 | — | — | US | disclosed |
| EP-1981880-B1 | USE OF 4-IMIDAZOLE DERIVATIVES FOR CNS DISORDERS | HOFFMANN LA ROCHE (CH) | 2010-02-24 | — | — | EP | disclosed |
| CN-101374832-A | Use of 4-imidazole derivatives for CNS disorders | HOFFMANN LA ROCHE (CH) | 2009-02-25 | — | — | CN | disclosed |
| EP-1981880-A2 | USE OF 4-IMIDAZOLE DERIVATIVES FOR CNS DISORDERS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-22 | — | — | EP | disclosed |
| US-20070197622-A1 | Methods for treating CNS disorders with 4-imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| WO-2007085556-A2 | USE OF 4-IMIDAZOLE DERIVATIVES FOR CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | disclosed |
| EP-0138358-A1 | The preparation and use of 2-[2-(1,4-benzodioxanyl)]-2-imidazoline in therapy | Farmos-Yhtyma Oy (FI) | 1985-04-24 | — | — | EP | disclosed |
| EP-0024829-B1 | 4-BENZYL- AND 4-BENZOYLIMIDAZOLE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | Farmos-Yhtyma Oy (FI) | 1984-04-25 | — | — | EP | disclosed |
| US-4443466-A | DIURETICS, SEDATIVES, ANALGESICS | Farmos-Yhtyma OY (Farmos Group Ltd.) (FI) | 1984-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197622-A1 | Methods for treating CNS disorders with 4-imidazole derivatives | CRY1, GPR119, MTNR1A | TAAR1 79/4885HTR1A 10/4885KCNH2 1162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.